News >

NICE Recommends Tisagenlecleucel for Relapsed/Refractory DLBCL

Gina Columbus @ginacolumbusonc
Published: Friday, Feb 01, 2019

Meindert Boysen

Meindert Boysen

The UK’s National Institute for Health and Care Excellence has authorized the use of the CAR T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received ≥2 lines of chemotherapy.1 The treatment will be made available through the Cancer Drugs Fund.



  1. NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma. NICE. Published February 1, 2019. Accessed February 1, 2019.
  2. Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. In: Proceedings from the 2018 ASH Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA. Abstract 577.
  3. Schuster SJ, Bishop MR, Tam C, et al. Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. In: Proceedings from the 2018 ASH Annual Meeting, December 1-4, 2018; San Diego, CA. Abstract 1684.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication